Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 17,257 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase 2 Study Clear all
Completed Phase 2 Interventional

Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00278382
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 23, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy

NCT05869682
View directory record Official record
Conditions
Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Bright White Light Therapy, Combination Drug Therapy, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

NCT00114959
View directory record Official record
Conditions
Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase, Myeloid Leukemia, Chronic, Chronic-Phase
Interventions
Homoharringtonine, Imatinib Mesylate
Drug
Lead sponsor
ChemGenex Pharmaceuticals
Industry
Eligibility
16 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT04318080
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
Tislelizumab
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Detroit, Michigan • Knoxville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 23, 2026, 10:27 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety Study of FluMist With and Without Ampligen

NCT01591473
View directory record Official record
Conditions
Influenza, Human
Interventions
Poly I:Poly C12U 50 ug, Poly I:Poly C12U 200 ug, Poly I:Poly C12U 500 ug, Poly I:Poly C12U 1250 ug, Placebo, FluMist
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
19 Years to 49 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 23, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

NCT01876641
View directory record Official record
Conditions
Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
Interventions
Vemurafenib + Cobimetinib, Decitabine
Drug
Lead sponsor
Mohammed M Milhem
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency

NCT02292654
View directory record Official record
Conditions
Sphingomyelin Lipidosis
Interventions
Olipudase alfa
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

NCT01585194
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 23, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade

NCT07459166
View directory record Official record
Conditions
Fentanyl Overdose, Fentanyl Poisoning
Interventions
Naloxone Hydrochloride, Fentanyl, Sterile Saline, CS-1103
Drug
Lead sponsor
Clear Scientific, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

NCT03264066
View directory record Official record
Conditions
Solid Tumors
Interventions
Cobimetinib, Atezolizumab, Atezolizumab Cohort 7
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Kansas City, Kansas • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)

NCT01953731
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib, Rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

NCT02871037
View directory record Official record
Conditions
Normal Healthy
Interventions
PF-05221304, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

NCT02085473
View directory record Official record
Conditions
Asthma, Healthy Subjects or Volunteers
Interventions
Tralokinumab 300 mg
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Clinical Trial Examining the Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5 and Vehicle Control

NCT03528369
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain
Interventions
CGS-200-1, CGS-200-5, CGS-200 Vehicle
Drug
Lead sponsor
Propella Therapeutics
Industry
Eligibility
35 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Clearwater, Florida • Tampa, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

NCT03980041
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
Interventions
IPI-549 (eganelisib), Nivolumab, Placebos
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Fort Wayne, Indiana • Baltimore, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 4 Interventional Results available

Nebivolol in Patients With Systolic Stage 2 Hypertension

NCT01057251
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 64 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Foley, Alabama • Montgomery, Alabama • Chino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

NCT00630331
View directory record Official record
Conditions
Influenza
Interventions
Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
11,404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

NCT00742027
View directory record Official record
Conditions
Classical Hodgkin's Lymphoma
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Duarte, California • Atlanta, Georgia • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

NCT00006227
View directory record Official record
Conditions
Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Steroid Cell Tumor
Interventions
Paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
85
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

A Study of CK-1827452 Infusion in Stable Heart Failure

NCT00624442
View directory record Official record
Conditions
Heart Failure
Interventions
CK-1827452, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Diego, California • Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 23, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

NCT00977470
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Erlotinib, Hydroxychloroquine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
4
States / cities
Stanford, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 23, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

NCT00322673
View directory record Official record
Conditions
Acute Myeloid Leukemia, AML
Interventions
XL999
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Alhambra, California • Los Angeles, California • Northridge, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

NCT06715683
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278 Batched method, Dose A, BMS-986278 Batched method, Dose B, BMS-986278 Continuous method
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

NCT02092922
View directory record Official record
Conditions
Advanced Multiple Myeloma
Interventions
Filanesib, KSP (Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 23, 2026, 10:27 AM EDT